

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
**Date of Report (Date of earliest event reported)**  
**June 13, 2022**

**Rocket Pharmaceuticals, Inc.**

**Delaware**  
(State or other jurisdiction of incorporation)

(Exact name of registrant as specified in its charter)

**001-36829**  
(Commission File Number)

**04-3475813**  
(IRS Employer Identification No.)

**9 Cedarbrook Drive**  
**Cranbury, NJ 08512**  
(Address of principal executive offices, including zip code)

**(609) 659-8001**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common stock, \$0.01 par value	RCKT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The 2022 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. (the “Company”), was held on June 13, 2022 (the “Annual Meeting”). At the Annual Meeting, there were present, in person or by proxy, holders of 55,510,402 shares of common stock, or approximately 86.03% of the total outstanding shares eligible to be voted. The holders present voted on the three proposals presented at the Annual Meeting as follows.

**Proposal One - Election of Directors**

The Company’s stockholders approved the election of nine directors to the Company’s Board of Directors (“Board”) by the following votes:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Elisabeth Björk, M.D., Ph.D.	47,847,554	561,549	7,101,299
Carsten Boess	47,072,823	1,336,280	7,101,299
Pedro Granadillo	43,070,107	5,338,996	7,101,299
Gotham Makker, M.D.	41,028,492	7,380,611	7,101,299
Fady Malik, M.D., Ph.D.	48,162,602	246,501	7,101,299
Gaurav Shah, M.D.	41,608,251	6,800,852	7,101,299
David P. Southwell	36,115,931	12,293,172	7,101,299
Roderick Wong, M.D.	40,759,519	7,649,584	7,101,299
Naveen Yalamanchi, M.D.	36,921,225	11,487,878	7,101,299

**Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm**

The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2022 by the following votes:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>
55,475,923	30,029	4,450

**Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers**

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the 2022 Annual Meeting of Stockholders pursuant to Section 14A of the Exchange Act, including the Compensation Discussion and Analysis, the Summary Compensation Table, and the narrative disclosures that accompany the compensation tables. The final votes were:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
42,160,877	6,240,249	7,977	7,101,299

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **Rocket Pharmaceuticals, Inc.**

Date: June 15, 2022

By: /s/ Gaurav Shah, MD

Gaurav Shah, MD

*Chief Executive Officer and Director*

---